AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUN 302 min read$ALXO

ALX ONCOLOGY HOLDINGS INC (ALXO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

ALX ONCOLOGY HOLDINGS INC (ALXO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001810182 false 0001810182 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29,

Original reporting
SEC EDGAR 8-K
Published Jun 30, 2026, 8:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$ALXO
Neutral
medium confidence
Mentioned
$ALXO
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ALXONeutralLow
01

Why it matters

The company reported a board chairman resignation (Corey Goodman) and appointment of Scott Garland as chairman, along with updated committee chair assignments.

02

Market read

This is a governance update that may affect sentiment and oversight expectations, but it does not include new financial guidance, deals, or regulatory/clinical catalysts.

03

What to watch

Traders should check whether the committee chair roles (audit/comp/gov) changed materially, as that can affect oversight intensity even without operational disclosures.

Relevance 6/10Novelty 5/10Timing: after-hours/filing update on June 30, 2026 (effective June 29)

Background

The filing is an SEC Form 8-K (Item 5.02) reporting director/officer changes and related committee composition updates.

Company-level read

Ticker impact

$ALXONeutralMedium confidence
Context

ALX Oncology disclosed Corey Goodman’s resignation as board chairman and named Scott Garland as the new chairman effective June 29, 2026.

Expected impact

Likely limited near-term impact unless investors interpret the change as signaling broader strategic or governance issues.

Evidence & confidence

The 8-K is a governance/committee reconstitution item (Item 5.02) with no stated disagreement, disputes, or new business terms; impact is therefore mostly sentiment/governance-driven.

Market effects

Sector

Minimal sector read-through; this is company-specific governance housekeeping rather than a biotech sector catalyst.

Regional

No clear regional spillover beyond Nasdaq-listed small/mid-cap sentiment.

Global

Primarily local to the issuer’s governance; no global market linkage indicated.

Counterpoint

What could challenge this read

Investors may overreact to a chairman change; since Goodman cited personal reasons and no disagreements, the market signal could be noise.

Key entities

  • company
    ALX Oncology Holdings Inc.

    Nasdaq-listed biotech issuer filing the 8-K reporting board leadership and committee changes.

  • person
    Corey Goodman, Ph.D.

    Resigned as Chairman of the board and from board committees effective June 29, 2026; stated personal reasons and no disagreements.

  • person
    Scott Garland

    Independent director appointed as Chairman effective June 29, 2026; also assigned to multiple committee roles.

Read at source← All news

Related articles

AUG 6
$ALXOMed

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ALX Oncology (Nasdaq: ALXO) reported Q2 2026 results and a corporate update. Cash, cash equivalents and investments were $153.4 million as of June 30, 2026. R&D fell to $13.1 million from $18.0 million year over year, and GAAP net loss was $18.0 million ($0.13/share). The company said ASPEN-09-Breast topline data from 80 patients is expected mid-2027, and ALX2004 safety data is expected in 2H 2026.

finanznachrichten.de7 min
AUG 6
$ALXOMed

ALX ONCOLOGY HOLDINGS INC (ALXO): Results of Operations and Financial Condition

ALX ONCOLOGY HOLDINGS INC (ALXO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 alxo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update – On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in com

SEC EDGAR 8-K7 min
AUG 8
$BPMedAI 8/10

BP Chair Who Sped Up Company’s Turnaround Fired Over Conduct

BP PLC fired Chairman Albert Manifold months after he took the role, citing serious concerns about governance standards, oversight, and conduct, according to BP’s board. BP shares fell about 9.3% after the news, with the stock at 529 pence in London. The move adds to leadership churn as BP seeks a turnaround under CEO Meg O’Neill.

energynow.com4 min
AUG 8
$000660.KSMed

SK Hynix said to mull options for US$3 billion Chongqing plant

SK Hynix is considering options for its Chongqing, China semiconductor packaging and testing facility, including possibly bringing in an investor to accelerate growth. People familiar said a potential stake sale could value the plant at about US$3 billion and SK Hynix may keep a minority stake. Separately, it plans a 54 trillion won (US$38 billion) South Korea expansion for DRAM and NAND.

businesstimes.com.sg3 min
AUG 8
$ZGMed

Zillow Lays Off 500+ Employees Amid $4 Million Q2 Net Loss

Zillow Group said Aug. 4 it will cut more than 500 jobs, about 7% of staff, its second layoff round this year after 200 cuts in January. The company reported Q2 2026 revenue of $772 million, up 18% year over year, but a $4 million net loss driven by a $36 million restructuring charge, citing a flat housing market.

whalesbook.com4 min